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To evaluate the balance between T-cell immunoglobulin and mucin domain (Tim) molecules(Tim)-1 and Tim-3 in
patients with aplastic anemia (AA), plasma IFN-γ and IL-4 levels were measured in patients with active AA (n = 41), AA
in remission (n = 29) and in healthy subjects (n = 40) by enzyme linked immunosorbent assay (ELISA). Using real-time
quantitative polymerase chain reaction (RT-PCR), the mRNA expression of IFN-γ, IL-4, Tim-1 and Tim-3 were studied in
all subjects. The results showed that the expression of Tim-3 in newly diagnosed patients was significantly deceased,
compared with the controls. Meanwhile, Tim-1 mRNA expression in the active AA group was not significantly reduced,
which resulted in a declined ratio of Tim-3/Tim-1 in patients with active disease. During the remission stages, the levels
of these transcription factors were comparable with those observed in the healthy controls. These findings are the first
data on the expression of the Tim-1 and Tim-3 molecules in AA. The reduced levels of Tim-3/Tim-1 in PBMCs during
the active stages of disease suggest that they may play a possible role in the pathogenesis and course of AA.
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Acquired aplastic anemia (AA) is mostly considered as an
immune-mediated bone marrow failure syndrome, which
differs from the other conditions associated with inherited
mechanisms [1]. Environmental exposure to, for example,
drugs, viruses, chemical and physical toxins, is thought to
trigger the aberrant immune response in some patients, but
most cases, the disease is classified as idiopathic immune-
mediated AA. Aberrant immunity, including abnormal im-
mune cells and molecules, contribute to the development
of acquired AA [2,3]. It has become evident that T helper 1
(Th1) and Th2 cells have pathogenetic importance in AA.
Specifically, activated antigen-presenting cells (APCs), espe-
cially dendritic cells (DCs), may promote the polarization
to Th1 cells and activate cytotoxic T lymphocytes (CTLs).
A variety of immune molecules, including interferon-γ
(IFN-γ), tumor necrosis factor-α (TNF-α) and interleukins
(ILs), which are produced by DCs, T lymphocytes and* Correspondence: snning@126.com
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tribute to the destruction of hematopoietic stem cells [3-6].
Recent investigations into the mechanisms that regu-
late the activation and function of CD4+ T cells have
shown that T cell immunoglobulin-mucin (Tim) proteins
are important regulators of immune function. Tim fam-
ily members are type I transmembrane proteins, with
extracellular immunoglobulin and mucin domains and
intracellular domains of different lengths. Tims are dif-
ferentially expressed on Th1 and Th2 cells [7,8]. The
Tim gene family includes eight genes in mice and three
genes in human. Studies in mice have indicated that
Tim-1 is involved in T helper cell differentiation and
suggested that the protein is a positive regulator of T cell
activity [9,10]. In humans, the gene encoding the Tim-1
protein has been considered as an important atopy sus-
ceptibility gene and is associated with Th2 T cell re-
sponses [11], suggesting that Tim-1 controls critical
regulatory pathways in the immune system.
Another member of Tim family proteins is Tim-3,
which in contrast to Tim-1, preferentially is expressed on
fully differentiated CD4+ Th1 cells, but not on Th2 cells,
and functions to inhibit aggressive Th1-mediated auto-s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Cytokine levels in AA patients and controls
(mean ± SD)
Groups Numbers of cases IFN-γ(pg/ml)
Controls 40 11.2 ± 5.2
AA (active) 41 44.2 ± 8.6*#
SAA 20 48.8 ± 6.8&
MAA 21 39.1 ± 7.5
AA (remission) 29 11.4 ± 4.9
*P < 0.05, AA (active) compared with normal controls;
#P < 0.05, AA (active) compared with AA(remission);
&P < 0.05, SAA compared with MAA.
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regarding the expression of Tim-1 and Tim-3 in patients
with acquired AA have been reported.
In the present study, we hypothesized that the imbalance
of Tim-1 and Tim-3 may play an important role in ac-
quired AA. The mRNA expression levels of Tim-1, Tim-3
and other cytokines were measured in the peripheral blood
mononuclear cells (PBMCs) of 41 newly diagnosed patients
with active AA, 29 AA patients in remission and 40 healthy
volunteers to investigate the possible role that Tim-1 and
Tim-3 may play in AA.
Methods
Patients and controls
In total, 41 newly diagnosed AA patients (22 females and
19 males; age range, 13–65 years; median age, 28 years)
were enrolled in this study. None of them had been trans-
fused or treated by immunosuppressive therapy prior to
sampling. Out of the 41 patients, 20 patients were diag-
nosed with severe AA (SAA) and 21 patients with moder-
ate AA (MAA) according to the criteria of Camitta et al.
[14]. The patients’ bone marrow cytogenetics was normal
in all cases, and Fanconi anemia was excluded in children
and adolescents based on family history and the presence
of typical physical characteristics. Patients complicated
with diabetes, hypertension, cardiovascular diseases, preg-
nancy, active infection, or connective tissue diseases, such
as systemic lupus erythematosus, were excluded. A total
of 29 AA patients (15 females and 14 males, age range
15–54 years, median 38 years) were in remission. All of
the patients met the diagnostic criteria of AA by bone
marrow biopsy and peripheral blood counts, as recom-
mended by the International Study of Aplastic Anemia
and Agranulocytosis [15]. Additionally, 40 healthy con-
trols were included (18 females and 22 males; age range,
12–63 years; median, 34 years). Enrollment took place be-
tween July 2011 and January 2014 in the Shandong Pro-
vincial Hospital Affiliated to Shandong University. Our
research was approved by the Medical Ethical Committee
of Shandong Provincial Hospital Affiliated to Shandong
University. An informed consent document was obtained
from each participant.
Isolation of RNA from PBMC
Fifteen milliliters of heparinized, venous peripheral blood
were collected from all patients and control individuals.
The blood was centrifuged and the heparinized plasma
was stored at −80°C. Mononuclear cells were isolated
from the heparinized blood by gradient centrifugation on
Ficoll-Paque (Pharmacia Diagnostics, Uppsala, Sweden).
The PBMC were then applied to an RNeasy mini-column
(Qiagen GmbH, Hilden, Germany), which was processed
according to the manufacturer’s recommendations. Total
RNA was eluted with 15 μl of RNase-free water and storedat −80°C. The amount of RNA was determined using
the Eppendorf Biophotometer (Brinkmann Instruments,
Westbury, NY, USA) and normalized to 1 μg/ml for each
subsequent real-time quantitative polymerase chain reac-
tion (RT-PCR) process.
Enzyme-linked immunosorbent assay (ELISA)
No significant cross-reactivity with human plasma IFN-γ
and IL-4 was determined using a commercial ELISA
(Jingmei, Beijing, China) according to the manufacturer’s
instructions. The lower detection limit of this assay was
2 pg/ml. The samples were run in duplicate.
Quantitative real-time polymerase chain reaction analysis
Multiplex real-time PCR was performed for IFN-γ, Tim-
1, Tim-3 and the endogenous control (β-actin) on ABI
PRISM®7500 Sequence Detection System (Applied Bio-
systems Foster City, CA, USA) using SYBRw Green
(Toyobo, Japan) as a double-strand DNA-specific bind-
ing dye. Amplification was carried out in a total volume
of 20 μl containing 0.5 mm of each primer, 10X SYBRw
Green and 0.5 mm of cDNA. The primers for all mRNA
assays were intron-spanning. The sequences of the amp-
lification primers are listed in Table 1.
The PCR reactions were cycled 40 times after initial
denaturation (95°C, 5 min) with the following parameters:
denaturation 95°C, 15 s; annealing 60°C, 15 s; extension
72°C, 35 s, with temperature transition rates of 20°C/s.
Fluorescence was acquired at extension 72°C, which was
below the product melting temperature (Tm), with a hold of
5 s. Melting curve analysis of the amplification products was
performed at the end of each PCR reaction. All reactions
were carried out in triplicate. ABI Sequence Detection
System software version 1.0 (PE Applied Biosystems, UK)
was used to determine the cycle number at which the fluor-
escence emission crossed the automatically determined Ct
value. All PCR products were visualized by electrophoresis
of 2% agarose gels stained with ethidium bromide.
Statistical analysis
The plasma levels were expressed as the mean ± SD and
statistical significance was determined by one-way ANOVA.
Figure 1 Relative mRNA expressions of Tim-1、Tim-3 and other
transcription factors. Freshly isolated human peripheral blood
mononuclear cells (PBMC) from AA patients and healthy controls
were quantified by RT-PCR. #P < 0.05, AA (newly-diagnosed) vs.
normal controls, *P < 0.05, AA (newly-diagnosed) vs. AA(remission).
Figure 2 The Tim-3/Tim-1 ratio in AA patients of newly-diagnosed
and AA patients in remission. The ratio of Tim-3/Tim-1 in active AA
patients was decreased significantly when compared with that of healthy
controls(#P< 0.05) and patients in remission(*P< 0.05).
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SPSS, Inc., Chicago, IL, USA). We used the comparative Ct
method (using arithmetic formulae) for the relative quantifi-
cation of cytokine mRNA according to relative expression
software tool (REST©) [16]. A probability value of P < 0.05
was considered statistically significant.
Results
Cytokine variations in AA patients
The plasma levels of IFN-γ in AA patients with active dis-
ease (P < 0.05) and AA patients in remission (P < 0.05) were
significantly increased compared with normal controls. Fur-
thermore, the expression level of IFN-γ in SAA patients
were higher than that in MAA patients (Table 1). No sig-
nificant differences were found between the patients in re-
mission and the normal controls. The levels of IL-4 were
below the detectable limit of the assay used. There was no
correlation between the IFN-γ or IL-4 levels and white
blood cell, hemoglobin, and platelet counts in the individ-
uals examined in our present study.
Comparison of mRNA expression levels of cytokines in
patients and controls
The data are presented as the fold change in gene expres-
sion normalized to an endogenous reference gene and
relative to healthy controls and were analyzed using the
REST software. IFN-γ was upregulated in active AA pa-
tients by 7.0-fold (P < 0.05), compared with controls, and
by 2.2-fold compared with remission patients (P > 0.05).
No significant difference in IFN-γ expression was found
between SAA patients and the MAA group (P > 0.05). For
all parameters, there was no significant difference between
patients in remission and the control group (Figure 1).
Tim-1 and Tim-3 expressions in patients and controls
The relative mRNA expression level of Tim-1 was de-
creased 1.4-fold in active patients, compared with healthy
controls (P > 0.05), and 1.2-fold, compared with remission
patients (P > 0.05). The decrease observed in Tim-3 ex-
pression was 3.3-fold (P < 0.05) and 1.1-fold (P > 0.05), in
active patients compared with controls and AA patients in
remission, respectively. The expression of Tim-1 in SAA
patients was found to be unchanged compared with the
MAA group. Tim-3 in SAA group displayed a trend to-
wards a decline, but the difference did not reach statistical
significance when compared with that of the MAA group.
The ratio of Tim-3/Tim-1 in normal control individuals
and patients with active disease
The ratio of Tim-3/Tim-1 in patients with active disease
was decreased significantly when compared with that in in-
dividuals in the normal group (P < 0.05) and AA patients in
remission (P < 0.05) (Figure 2). The ratio of Tim-3/Tim-1
in the AA remission group had a trend towards elevation,but this difference did not reach statistical significance
when compared with that of control group. Interestingly,
the ratio of Tim-3/Tim-1 was found to be unchanged in
SAA patients compared to MAA ones. Statistically signifi-
cant differences were not found in patients in remission,
compared to healthy controls (P > 0.05).
Discussion
Aplastic anemia (AA) is a rare, potentially life-threatening
failure of hematopoiesis that is characterized by pancyto-
penia and bone marrow aplasia. It was originally thought
to result from a direct toxic effect on hematopoietic stem
cells, leading to a decrease in their numbers. An increase
in monocyte-derived DCs (DC1) shifted from the stable
form to the active one, promoting Th0 cells to polarize
into Th1 cells. The alterations in Th1 lymphocyte function
and cytokines have been intensively investigated as
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for diagnosis and prognosis [17,18]. In the current study,
we examined the function of Th-associated transcription
factors in regulating Tim-1 and Tim-3 expression. Patients
with active AA disease demonstrated decreased mRNA
expression levels of Tim-3, while the levels of Tim-1 in
patients were comparable to the levels of healthy controls,
thereby suggesting that the balance of Tim-3 and Tim-1
may play an important role in AA pathogenesis.
Tim-3 is a cell surface protein that is expressed at the late
stages of IFN-γ-secreting CD4+ Th1 cell differentiation,
and it is constitutively expressed in dendritic cells. Altered
expression levels of Tim-3, which often correlates with dis-
ease activity, have been reported in various experimental
and human autoimmune disorders. The administration of a
Tim-3-blocking antibody inhibited the suppression activity
of Tregs, thereby resulting in augmented production of
IFN-γ [19]. Moreover, Ju recently reported that following
Tim-3 knockdown using specific shRNAs, a significant in-
crease in IFN-γ production from hepatic CD8+ T cells was
observed in a HBV mouse model [20]. Our previous study
confirmed that the protein levels of Tim-3 in active AA pa-
tients were significantly decreased, compared with normal
controls [21]. The observed reduction in Tim-3 protein and
mRNA levels in the CD4+ T cells of SAA patients was
more obvious than in MAA patients, thereby implying that
reduced Tim-3 expression on CD4+ T cells may lead to
more intensive CD4+ T cell accumulation. Therefore, up-
regulating the expression of Tim-3 in AA patients may also
represent a therapeutic approach against AA.
Recently, a new gene encoding human hepatitis A
virus cellular receptor (HAVCR), which was also identi-
fied as T-cell immunoglobulin-and mucin-domain-
containing molecule-1 (Tim-1), has attracted much
attention in the field of autoimmune diseases. Tim-1 is
a type I transmembrane protein, with extracellular im-
munoglobulin and mucin domains and intracellular do-
mains of various lengths. Tim-1 was first identified in
the African green monkey, and later in humans, as
HAVCR, the receptor exploited by hepatitis A for viral
entry. It was reported that Tim-1 mRNA is expressed by
Th2 cells, but not Th1 cells, in humans and mice. Fur-
thermore, Tim-1 ligation enhanced the proliferation of
T cells and, in Th2 cells, the production of IL-4. In vivo
administration of anti-Tim-1 antibodies increased pro-
duction of both IL-4 and IFN-γ in unpolarized cells [9].
In our present study, AA patients had increased IFN-γ
and an unchanged Tim-1 mRNA level compared to
controls. Tim-1 expression patterns may be related to
differences in Th1/Th2 profiles. Umetsu et al. showed
that Tim-1 expression is highly increased on newly acti-
vated cells. However, with time, Th1 cells lose Tim-1 ex-
pression, while it is sustained on Th2 cells [9,11]. Thus,
the trend of down-regulated expression of Tim-1 in AApatients is in agreement with the exaggerated Th1 re-
sponse in AA patients. Although the alteration of Tim-1
or Tim-3 mRNA expression is evident in patients with
various autoimmune diseases, such as systemic lupus er-
ythematosus [22], asthma and other autoimmune dis-
eases [23], little information is available regarding the
interactions of these transcription factors in AA.
Our results confirmed a reciprocal pattern in mRNA ex-
pression of Tim-1 and Tim-3 in AA. Specifically, the mRNA
levels of Tim-3 were significantly decreased in active AA pa-
tients, compared to controls and patients in remission, while
Tim-1 levels were not significantly changed in AA patients.
The ratio of Tim-3/Tim-1 in patients with active disease
was significantly reduced when compared with that of the
normal groups and AA patients in remission. Regulating the
balance of Tim-1 and Tim-3 in AA patients may also be a
therapeutic approach against AA, although further studies
are warranted to validate this concept.
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